Bristol-Myers Squibb Company (BMY) Shares are Down -0.88%

Bristol-Myers Squibb Company (BMY) : During the past 4 weeks, traders have been relatively bearish on Bristol-Myers Squibb Company (BMY), hence the stock is down -21.28% when compared to the S&P 500 during the same period. However, in the past 1 week, the selling of the stock is down by -0.22% relative to the S&P 500. The 4-week change in the price of the stock is -21.44% and the stock has fallen -0.88% in the past 1 week.

Company shares have received an average consensus rating of Hold for the current week The stock has recorded a twenty day Moving Average of 7.86% and the fifty day Moving Average is 15.88%. Bristol-Myers Squibb Company has dropped 17.15% during the last three month period . Year-to-Date the stock performance stands at -13.6%.

Bristol-Myers Squibb Company (BMY) : The most positive equity analysts on Bristol-Myers Squibb Company (BMY) expects the shares to touch $100, whereas, the least positive believes that the stock will trade at $48 in the short term. The company is covered by 13 Wall Street Brokerage Firms. The average price target for shares are $68.39 with an expected fluctuation of $12.94 from the mean.


Bristol-Myers Squibb Company (NYSE:BMY): stock turned positive on Friday. Though the stock opened at $58.76, the bulls momentum made the stock top out at $59.4 level for the day. The stock recorded a low of $58.54 and closed the trading day at $58.77, in the green by 0.02%. The total traded volume for the day was 7,845,194. The stock had closed at $58.76 in the previous days trading.

Bristol-Myers Squibb Company (BMS) is engaged in the discovery, development, licensing, manufacturing, marketing, distribution and sale of biopharmaceutical products across the world. The Companys products are sold to wholesalers, retail pharmacies, hospitals, government entities and the medical profession. The Company manufactures its products in the United States, Puerto Rico and in six foreign countries. The Company promotes the use of its products directly to healthcare professionals and providers, such as doctors, nurse practitioners, physician assistants, pharmacists, technologists, hospitals, Pharmacy Benefit Managers (PBMs) and Managed Care Organizations (MCOs). It also provides information about the use of its products to consumers in the United States through direct-to-consumer print, radio, television, and digital advertising and promotion. In addition, the Company holds rights to F001287, which is a preclinical, small-molecule IDO1-inhibitor.

Comments (0)

Leave a Reply

Your email address will not be published. Required fields are marked *